Xenetic Biosciences, Inc. (XBIO)
$3.96+$0.01 (+0.25%) Today
Latest XBIO Insider Trades
James F. Parslow - OfficerGrant or award100,000 sh
James F. Parslow - OfficerXenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
No Form 4 activity for XBIO in the last 90 days.
9 Form 4 filings on record, the earliest from Dec 13, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| James F. Parslow - Officer | Grant or award | Common Stock | 100,000 | $0.00 | - | |
| Alexey Andreevich Vinogradov - Director | Grant or award | Stock Options | 2,500 | $0.00 | - | |
| Firdaus J. Dastoor - Director | Grant or award | Stock Options | 2,500 | $0.00 | - | |
| Roger D. Kornberg - Director | Grant or award | Stock Options | 2,500 | $0.00 | - | |
| Grigory G. Borisenko - Director | Grant or award | Stock Options | 2,500 | $0.00 | - | |
| Firdaus J. Dastoor - Director | Grant or award | Stock Options | 2,500 | $0.00 | - | |
| Grigory G. Borisenko - Director | Grant or award | Stock Options | 2,500 | $0.00 | - | |
| Roger D. Kornberg - Director | Grant or award | Stock Options | 2,500 | $0.00 | - | |
| Alexey Andreevich Vinogradov - Director | Grant or award | Stock Options | 2,500 | $0.00 | - |
Xenetic Biosciences, Inc. (XBIO) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-04-23. The full record for XBIO runs to 9 Form 4 filings, the earliest from 2024-12-13. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of XBIO were filed in the last 90 days.
No insider sales of XBIO were filed in the last 90 days.
This page tracks XBIO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add XBIO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
$XBITXBiotech Inc.
$XCAIXConstitution Capital Access Fund, LLC
$XCBEX3 Acquisition Corp. Ltd.
$XCHXCHG Ltd
$XCPIXCarlyle AlpInvest Private Markets Fund
$XEX-Energy, Inc.
$XELAExela Technologies, Inc.
$XFLHXFLH Capital Corp
$XFLTXAI Octagon Floating Rate Alternative Income Trust
$XHFIXHartford Schroders Private Opportunities FundEvery Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.